BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
SEATTLE, Nov. 15, 2016 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company’s lead product candidate tucatinib (also known as ONT-380) will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) to be held December 6-10 in San Antonio, TX.
The Phase 1b “Triplet” poster presentation will include more mature progression-free survival (PFS) and safety data not included in the abstract posted on the SABCS website, which was as of May 2016.
Details of Poster Presentations:
A Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine (C) and Trastuzumab (T) in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (MBC) (HER2CLIMB)
First Author: Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session: OT1-02-09, Ongoing Trials – Chemotherapy
Date/Time: Wednesday, December 7, 2016; 5:00 p.m.–7:00 p.m. CST
Efficacy Results of a Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in HER2+ Metastatic Breast Cancer (MBC), Including Patients (pts) with Brain Metastases (mets)
First Author: Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session: P4-21-01, Treatment: HER2-Targeted Therapy
Date/Time: Friday, December 9, 2016; 7:30 a.m.–9:00 a.m. CST
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.
Contacts: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected] Media: Brad Miles BMC Communications 917-570-7340 [email protected]
